全文获取类型
收费全文 | 33482篇 |
免费 | 2227篇 |
国内免费 | 200篇 |
专业分类
耳鼻咽喉 | 320篇 |
儿科学 | 580篇 |
妇产科学 | 452篇 |
基础医学 | 4725篇 |
口腔科学 | 919篇 |
临床医学 | 3457篇 |
内科学 | 7098篇 |
皮肤病学 | 668篇 |
神经病学 | 3755篇 |
特种医学 | 1963篇 |
外科学 | 5342篇 |
综合类 | 188篇 |
一般理论 | 7篇 |
预防医学 | 1390篇 |
眼科学 | 683篇 |
药学 | 1983篇 |
中国医学 | 68篇 |
肿瘤学 | 2311篇 |
出版年
2024年 | 19篇 |
2023年 | 241篇 |
2022年 | 231篇 |
2021年 | 893篇 |
2020年 | 632篇 |
2019年 | 823篇 |
2018年 | 946篇 |
2017年 | 806篇 |
2016年 | 934篇 |
2015年 | 1145篇 |
2014年 | 1376篇 |
2013年 | 1661篇 |
2012年 | 2704篇 |
2011年 | 2819篇 |
2010年 | 1689篇 |
2009年 | 1507篇 |
2008年 | 2400篇 |
2007年 | 2405篇 |
2006年 | 2241篇 |
2005年 | 2202篇 |
2004年 | 1986篇 |
2003年 | 1817篇 |
2002年 | 1675篇 |
2001年 | 306篇 |
2000年 | 224篇 |
1999年 | 282篇 |
1998年 | 319篇 |
1997年 | 237篇 |
1996年 | 187篇 |
1995年 | 164篇 |
1994年 | 131篇 |
1993年 | 124篇 |
1992年 | 77篇 |
1991年 | 61篇 |
1990年 | 69篇 |
1989年 | 46篇 |
1988年 | 44篇 |
1987年 | 31篇 |
1986年 | 32篇 |
1985年 | 34篇 |
1984年 | 44篇 |
1983年 | 29篇 |
1982年 | 38篇 |
1981年 | 28篇 |
1980年 | 21篇 |
1979年 | 15篇 |
1978年 | 13篇 |
1977年 | 16篇 |
1975年 | 12篇 |
1974年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
991.
992.
Troch M Kiesewetter B Dolak W Jaeger U Püspök A Müllauer L Chott A Raderer M 《Annals of hematology》2012,91(5):723-728
Mucosa-associated lymphoid tissue (MALT) lymphomas are B cell neoplasms which commonly affect the gastrointestinal (GI) tract.
Gastrointestinal MALT lymphomas rarely show plasmacytic differentiation (PCD), and limited data on the potential influence
of the anti-CD20 antibody rituximab (R) on PCD exist in the current literature. We have retrospectively analyzed patients
with GI MALT lymphomas treated with R-containing regimens because restaging is routinely performed by repeated biopsies with
pathohistological response assessment. Twenty-one patients with GI MALT lymphoma were identified to have undergone R-containing
therapy. In 19 patients, the lymphoma originated in the stomach, while the colon was the primarily affected organ in two cases.
Four patients received R monotherapy and 17 combinations of R with various chemotherapeutic agents. Only two patients with
gastric MALT lymphoma had PCD before initiation of therapy. In 7 of 19 patients (37%) without PCD at diagnosis, restaging
revealed PCD after or while on treatment with R-containing regimens. Out of these seven patients, only one patient had a complete
response as opposed to 10/12 without PCD. These data suggest that R or R-containing treatment regimens may not optimally eradicate
the plasma cell component and thus lead to PCD in patients with GI MALT lymphoma. In view of this, rebiopsy and histological
re-assessment appear mandatory in patients failing/relapsing after R-containing regimens. 相似文献
993.
Thoennissen GB Thoennissen NH Fritz F Hilbig A Kerkhoff A Liersch R Krug U Koschmieder S Müller-Tidow C Mesters R Kropff M Berdel WE 《Annals of hematology》2012,91(9):1419-1425
The acronym POEMS syndrome stands for a rare multi-system disorder, comprised of polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes. Here, we present a single-center report of a series of five POEMS patients treated with melphalan high-dose therapy (HDT) with subsequent autologous blood stem cell transplantation (ABSCT). After a median follow-up of 52 months from time of diagnosis (range, 15-192) and a median follow-up of 18 months after ABSCT (range, 11-120), all patients were alive. Overall, no severe transplantation-associated complications such as engraftment syndrome or peri- or post-transplant death were noted. In two cases, HDT followed by ABSCT resulted in a complete hematologic response; in the additional three cases, partial responses (PR) were achieved including one very good hematologic PR. Only one patient with initial PR developed progressive disease nearly 2.5 years after transplantation. Consequently, a second HDT with ABSCT was successfully applied resulting in clinical improvement and hematologic PR. In line with previous single-center reports, melphalan HDT followed by ABSCT proved to be a first-line treatment option with tolerable side effects in severely affected POEMS patients with progressing symptoms. 相似文献
994.
Voskaridou E Ladis V Kattamis A Hassapopoulou E Economou M Kourakli A Maragkos K Kontogianni K Lafioniatis S Vrettou E Koutsouka F Papadakis A Mihos A Eftihiadis E Farmaki K Papageorgiou O Tapaki G Maili P Theohari M Drosou M Kartasis Z Aggelaki M Basileiadi A Adamopoulos I Lafiatis I Galanopoulos A Xanthopoulidis G Dimitriadou E Mprimi A Stamatopoulou M Haile ED Tsironi M Anastasiadis A Kalmanti M Papadopoulou M Panori E Dimoxenou P Tsirka A Georgakopoulos D Drandrakis P Dionisopoulou D 《Annals of hematology》2012,91(9):1451-1458
Haemoglobinopathies are the most common hereditary disorders in Greece. Although there is a successful national prevention program, established 35 years ago, there is lack of an official registry and collection of epidemiological data for haemoglobinopathies. This paper reports the results of the first National Registry for Haemoglobinopathies in Greece (NRHG), recently organized by the Greek Society of Haematology. NRHG records all patients affected by thalassaemia major (TM), thalassaemia intermedia (TI), "H" Haemoglobinopathy (HH) and sickle cell disease (SCD). Moreover, data about the annual rate of new affected births along with deaths, between 2000 and 2010, are reported. A total of 4,506 patients are registered all over the country while the number of affected newborns was significantly decreased during the last 3 years. Main causes for still having affected births are: (1) lack of medical care due to financial reasons or low educational level; (2) unawareness of time limitations for prenatal diagnosis (PD); due either to obstetricians' malpractice or to delayed demand of medical care of couples at risk; and (3) religious, social or bioethical reasons. Cardiac and liver disorders consist main causes for deaths while life expectancy of patients lengthened after 2005 (p < 0.01). The NRHG of patients affected by haemoglobinopathies in Greece provides useful data about the haemoglobinopathies in the Greek population and confirms the efficacy of the National Thalassaemia Prevention Program on impressively decreasing the incidence of TM and sickle cell syndromes. 相似文献
995.
996.
Papaconstantinou I Karakatsanis A Gazouli M Polymeneas G Voros D 《European journal of gastroenterology & hepatology》2012,24(3):223-228
Hepatocellular carcinoma and cholangiocarcinoma constitute the majority of primary malignant tumors located in the liver, with hepatocellular carcinoma accounting for approximately 80% of these tumors and cholangiocarcinoma representing the remaining 20%. Both are aggressive malignancies, heterogeneous in terms of biological activities and clinical behavior, with dismal outcomes and an increasing incidence worldwide. Radical surgical resection remains the gold standard to date, as adjuvant therapeutic modalities have failed to show a consistent and adequate curative response. However, radical surgical resection is not feasible in most of the patients with such tumors, as tumor size or functional status of the parenchyma does not permit extended hepatic resection. In addition, patients who undergo curative resection often have a high rate of relapse. Multimodal therapeutic approaches, such as the combination of invasive methods (surgical resection, radiofrequency ablation, and two-step or three-step procedures with intermittent portal vein embolization) with interferon-α, systemic chemotherapy, or transarterial catheter embolization, may prolong survival in some patients, but have, however, failed to demonstrate satisfactory results. Therefore, an obvious need emerges for the discovery of new biomarkers to understand the events leading to hepatocarcinogenesis, to relate different phenotypes with differences in clinical behavior and prognosis, and, if possible, to predict response rates to adjuvant therapeutic modalities or, furthermore, to establish novel mechanism-based treatments for hepatic tumors. 相似文献
997.
Valent P Gastl G Geissler K Greil R Hantschel O Lang A Linkesch W Lion T Petzer AL Pittermann E Pleyer L Thaler J Wolf D 《Critical reviews in oncology/hematology》2012,82(3):370-377
Nilotinib is a second generation ABL tyrosine kinase inhibitor (TKI) that exerts major anti-leukemic effects in newly diagnosed patients with chronic myeloid leukemia (CML) as well as in most patients with imatinib-resistant CML. In freshly diagnosed patients, the anti-leukemic activity of nilotinib exceeds the efficacy of imatinib, and although long-term data for nilotinib are not available yet, the drug has recently been approved for firstline treatment of chronic phase CML in various countries. Still however, several questions concerning the optimal dose, follow-up parameters, long-term safety, and patient selection remain open. Likewise, it remains uncertain whether both Sokal low-risk and high-risk patients should receive nilotinib as frontline therapy in the future. Another question is whether nilotinib can completely eradicate CML in a subset of patients. Furthermore, it remains unclear whether and what comorbidity must be regarded as relative or absolute contra-indication for this TKI. To discuss these issues, the Austrian CML Working Group organized a series of meetings in 2010. In the current article, the outcomes from these discussions are summarized and presented together with recommendations for frontline use of TKIs in various groups of patients with CML. These recommendations should assist in daily practice as well as in the preparation and conduct of clinical trials. 相似文献
998.
999.
1000.